Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Information for investors
Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.
Latest news and updates
Our CEO, Nigel Theobald, has written an article for Drug Discovery Today about the emerging vaccine delivery systems for COVID-19. He talks about how functionalised silica nanoparticles, like Nuvec®, offer a potentially safe and effective [...]
After the release of our interim results this week, we're pleased to share another interview between N4 Pharma's CEO, Nigel Theobald, and Directors Talk. Nigel discusses the progress made with Nuvec® research projects in the [...]
N4 Pharma's CEO, Nigel Theobald, has spoken to Directors Talk to give an update on our Covid-19 proof of concept project, and our ongoing work to show Nuvec®'s potential use with multiple vaccines. Watch the [...]